ReNAgade Therapeutics, a Cambridge, MA-based biotechnology company developing RNA medicines, raised $300M in Series A funding.
The round was led by MPM BioImpact and F2 Ventures.
The company intends to use the funds to expand operations, and its development efforts.
Founded by MPM BioImpact, and CEO Amit D. Munshi, ReNAgade is a biotechnology company focused on advancing RNA medicines to treat disease anywhere in the body. The company combines its novel RNA delivery platforms with a comprehensive and a complementary RNA platform allowing for an all-RNA system for coding, editing, and gene insertion tools to develop new medicines.
ReNAgade has built a comprehensive and complementary platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA system. The company has an established joint venture with Orna Therapeutics Inc., combining its delivery platform with Orna’s circular RNA technology. Subsequently, Orna has entered into a collaboration with Merck, which includes technologies developed under the Orna/ReNAgade JV.
The team includes Ansbert Gadicke, M.D., (also Managing Partner of MPM BioImpact), Pete Smith, Ph.D., (Chief Scientific Officer and an Executive Partner at MPM BioImpact), Ciaran Lawlor, Ph.D. joins (Chief Operating Officer from Boston Consulting Group) and Brian Shuster (Chief Business Officer from Bristol Myers Squibb).
FinSMEs
24/05/2023